DK2158332T3 - Prognoseforudsigelse til melanomcancer - Google Patents
Prognoseforudsigelse til melanomcancer Download PDFInfo
- Publication number
- DK2158332T3 DK2158332T3 DK08766967.7T DK08766967T DK2158332T3 DK 2158332 T3 DK2158332 T3 DK 2158332T3 DK 08766967 T DK08766967 T DK 08766967T DK 2158332 T3 DK2158332 T3 DK 2158332T3
- Authority
- DK
- Denmark
- Prior art keywords
- expression
- melanoma
- prognosis
- mpms
- determining
- Prior art date
Links
- PWPJGUXAGUPAHP-UHFFFAOYSA-N lufenuron Chemical compound C1=C(Cl)C(OC(F)(F)C(C(F)(F)F)F)=CC(Cl)=C1NC(=O)NC(=O)C1=C(F)C=CC=C1F PWPJGUXAGUPAHP-UHFFFAOYSA-N 0.000 title 1
- 230000014509 gene expression Effects 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 124
- 206010028980 Neoplasm Diseases 0.000 claims description 103
- 108090000623 proteins and genes Proteins 0.000 claims description 103
- 201000001441 melanoma Diseases 0.000 claims description 78
- 238000004393 prognosis Methods 0.000 claims description 64
- 239000003550 marker Substances 0.000 claims description 34
- 238000002493 microarray Methods 0.000 claims description 33
- 238000004458 analytical method Methods 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 18
- 108091034117 Oligonucleotide Proteins 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 238000011529 RT qPCR Methods 0.000 claims description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 7
- 238000013528 artificial neural network Methods 0.000 claims description 7
- 239000000758 substrate Substances 0.000 claims description 7
- 238000012706 support-vector machine Methods 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000003018 immunoassay Methods 0.000 claims description 4
- 238000007636 ensemble learning method Methods 0.000 claims description 3
- 235000021243 milk fat Nutrition 0.000 claims 3
- 238000012880 independent component analysis Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 85
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 45
- 210000001519 tissue Anatomy 0.000 description 41
- 201000011510 cancer Diseases 0.000 description 40
- 239000013615 primer Substances 0.000 description 28
- 238000003753 real-time PCR Methods 0.000 description 27
- 238000012360 testing method Methods 0.000 description 25
- 238000011282 treatment Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 22
- 238000010200 validation analysis Methods 0.000 description 22
- 229920001184 polypeptide Polymers 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 238000007418 data mining Methods 0.000 description 17
- 239000002157 polynucleotide Substances 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 17
- 238000012549 training Methods 0.000 description 17
- 238000013459 approach Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000010837 poor prognosis Methods 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 238000003757 reverse transcription PCR Methods 0.000 description 13
- 238000013461 design Methods 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 238000005259 measurement Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 101710191666 Lactadherin Proteins 0.000 description 9
- 102100039648 Lactadherin Human genes 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000009098 adjuvant therapy Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000010208 microarray analysis Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 206010027476 Metastases Diseases 0.000 description 7
- 238000002790 cross-validation Methods 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000002123 RNA extraction Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000011223 gene expression profiling Methods 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 108010078049 Interferon alpha-2 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 208000030381 cutaneous melanoma Diseases 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229960003507 interferon alfa-2b Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012775 microarray technology Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 201000003708 skin melanoma Diseases 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 229920001076 Cutan Polymers 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 240000008168 Ficus benjamina Species 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000009274 differential gene expression Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 239000013074 reference sample Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GPAAEXYTRXIWHR-UHFFFAOYSA-N (1-methylpiperidin-1-ium-1-yl)methanesulfonate Chemical compound [O-]S(=O)(=O)C[N+]1(C)CCCCC1 GPAAEXYTRXIWHR-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 230000007321 biological mechanism Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000013101 initial test Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000003909 pattern recognition Methods 0.000 description 2
- 238000011240 pooled analysis Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 240000005020 Acaciella glauca Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091029845 Aminoallyl nucleotide Proteins 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 1
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000976806 Genea <ascomycete fungus> Species 0.000 description 1
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 1
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 1
- 101001129851 Homo sapiens Paired immunoglobulin-like type 2 receptor alpha Proteins 0.000 description 1
- 101000773122 Homo sapiens Thioredoxin domain-containing protein 5 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 102100031651 Paired immunoglobulin-like type 2 receptor alpha Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100030269 Thioredoxin domain-containing protein 5 Human genes 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012308 immunohistochemistry method Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007837 multiplex assay Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003196 serial analysis of gene expression Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Biomedical Technology (AREA)
- Databases & Information Systems (AREA)
- Primary Health Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (13)
1. Fremgangsmåde til at bestemme prognosen for melanom hos en patient, hvilken fremgangsmåde omfatter: (i) at bestemme ekspressionsniveauet af en melanom-prognostisk markør (MPM), som er mælkefedtkugle-EGF-faktor-8-protein (MFGE8), eller af en prognostisk signatur, omfattende to eller flere MPM'er, hvoraf mindst én er MFGE8, i en melanomtumorprøve fra patienten, (ii) at benytte en forudsigelsesmodel, tilvejebragt ved at anvende en forudsigelsesfremgangsmåde på ekspressionsniveauer af MPM'en eller af den prognostiske signatur i prognostisk gode og dårlige tumorprøver, (iii) at tilvejebringe en prognose.
2. Fremgangsmåde til at bestemme egnetheden af en melanompatient til et lægemiddelforsøg, hvilken fremgangsmåde omfatter: (i) at bestemme ekspressionsniveauet af en MPM, som er mælkefedtkugle-EGF-faktor-8-protein (MFGE8), eller af en prognostisk signatur omfattende to eller flere MPM'er, hvoraf mindst én er MFGE8, i en melanomtumorprøve fra patienten, (ii) at benytte en forudsigelsesmodel, tilvejebragt ved at anvende en forudsigelsesfremgangsmåde på ekspressionsiveauer af MPM'en eller af den prognostiske signatur i prognostisk gode og dårlige tumorprøver, (iii) at bestemme egnetheden af patienten til forsøget.
3. Fremgangsmåde ifølge krav 1 eller krav 2, hvor én af de andre MPM'ere er valgt fra Tabel 1.
4. Fremgangsmåde ifølge krav 1, hvor forudsigelsesfremgangsmåden er valgt fra gruppen bestående af lineære modeller, understøtningsvektormaskiner, neurale netværk, klassifikations- og regressionstræer, ensembleindlæringsmetoder, diskriminantanalyse, nærmeste-nabo-fremgangsmåde, bayesianske net eller uafhængig komponentanalyse.
5. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor trinnet at bestemme ekspressionsniveauet af en MPM eller af en prognostisk signatur udføres ved at detektere ekspressionsniveauet af mRNA af hvert gen eller cDNA af hvert gen.
6. Fremgangsmåde ifølge krav 5, hvor trinnet at bestemme ekspressionsniveauet af en MPM eller af en prognostisk signatur udføres ved anvendelse af et oligonukleotid, der er komplementært til mindst en del af cDNA'et, eller udføres ved anvendelse af en qPCR-fremgangsmåde ved anvendelse af en fremadprimer og en bagudprimer.
7. Fremgangsmåde ifølge krav 5, hvor trinnet at bestemme ekspressionsniveauet af en MPM eller af en prognostisk signatur udføres ved anvendelse af en indretning ifølge krav 12 eller krav 13.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 4, hvor trinnet at bestemme ekspressionsniveauet af en MPM eller af en prognostisk signatur udføres ved at detektere ekspressionsniveauet af proteinet for hver markør eller udføres ved at detektere ekspressionsniveauet af proteinet eller peptidet for hver markør.
9. Fremgangsmåde ifølge krav 7 eller krav 8, hvor detekteringstrinnet udføres ved anvendelse af et antistof rettet mod hver markør.
10. Fremgangsmåde ifølge kravene 7 eller 8, hvor detekteringstrinnet udføres ved anvendelse af en sandwich-immunoassay-fremgangsmåde.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 9 eller 10, hvor antistoffet er et monoklonalt antistof eller er et polyklonalt antiserum.
12. Anvendelse af en indretning til at bestemme prognose af melanom ved at bestemme ekspressionsniveauet af MFGE8 eller af en prognostisk signatur omfattende to eller flere MPM'er, hvor mindst én af disse er MFGE8, hvilken indretningen omfatter: et substrat, der har én eller flere positioner derpå, idet hver position har to eller flere oligonukleotider derpå, og hvert oligonukleotid er valgt blandt den ene eller de flere MPM'er, hvor mindst én af MPM'erne er mælkefedtkugle-EGF-faktor-8-protein (MFGE8).
13. Anvendelse ifølge krav 12, hvor indretningen er et array (f.eks. mikroarray), eller hvor én af de andre MPM'er er valgt fra Tabel 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ555363A NZ555363A (en) | 2007-05-24 | 2007-05-24 | Prognosis prediction for melanoma cancer |
| PCT/NZ2008/000118 WO2008143533A1 (en) | 2007-05-24 | 2008-05-23 | Prognosis prediction for melanoma cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2158332T3 true DK2158332T3 (da) | 2017-05-01 |
Family
ID=40032133
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08766967.7T DK2158332T3 (da) | 2007-05-24 | 2008-05-23 | Prognoseforudsigelse til melanomcancer |
| DK16203301.3T DK3176270T3 (da) | 2007-05-24 | 2008-05-23 | Forudsigelse af melanomcancerprognose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16203301.3T DK3176270T3 (da) | 2007-05-24 | 2008-05-23 | Forudsigelse af melanomcancerprognose |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US8822149B2 (da) |
| EP (2) | EP3176270B1 (da) |
| JP (5) | JP5943315B2 (da) |
| CN (1) | CN101743327B (da) |
| AR (1) | AR066725A1 (da) |
| AU (1) | AU2008253836B2 (da) |
| CA (1) | CA2725602A1 (da) |
| CL (1) | CL2008001517A1 (da) |
| DK (2) | DK2158332T3 (da) |
| ES (2) | ES2821300T3 (da) |
| NZ (1) | NZ555363A (da) |
| PT (2) | PT2158332T (da) |
| SG (2) | SG10201912289SA (da) |
| TW (2) | TWI609967B (da) |
| UY (1) | UY31105A1 (da) |
| WO (1) | WO2008143533A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120135415A1 (en) * | 2002-11-15 | 2012-05-31 | Morehouse School Of Medicine | Detecting cancer with anti-cxcl13 and anti-cxcr5 antibodies |
| WO2008117067A2 (en) | 2007-03-27 | 2008-10-02 | Carl Arne Krister Borrebaeck | Protein signature/markers for the detection of adenocarcinoma |
| JP5683280B2 (ja) * | 2011-01-04 | 2015-03-11 | 株式会社日立製作所 | 診療支援システム |
| CN102617734B (zh) * | 2011-12-28 | 2013-09-04 | 暨南大学 | 抗FGF-2抗体Dab-2及其应用 |
| US9336302B1 (en) | 2012-07-20 | 2016-05-10 | Zuci Realty Llc | Insight and algorithmic clustering for automated synthesis |
| US9355105B2 (en) * | 2012-12-19 | 2016-05-31 | International Business Machines Corporation | Indexing of large scale patient set |
| CA2904283A1 (en) | 2013-03-14 | 2014-10-02 | Castle Biosciences, Inc. | Methods for predicting risk of metastasis in cutaneous melanoma |
| US10687711B2 (en) * | 2015-05-05 | 2020-06-23 | Medizinische Universität Wien | Computerized device and method for processing image data |
| WO2018009887A1 (en) * | 2016-07-08 | 2018-01-11 | University Of Hawaii | Joint analysis of multiple high-dimensional data using sparse matrix approximations of rank-1 |
| US11205103B2 (en) | 2016-12-09 | 2021-12-21 | The Research Foundation for the State University | Semisupervised autoencoder for sentiment analysis |
| US10692605B2 (en) | 2018-01-08 | 2020-06-23 | International Business Machines Corporation | Library screening for cancer probability |
| TW202018727A (zh) | 2018-11-09 | 2020-05-16 | 財團法人工業技術研究院 | 整體式學習預測方法與系統 |
| EP3935581A4 (en) | 2019-03-04 | 2022-11-30 | Iocurrents, Inc. | DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| CN112200391B (zh) * | 2020-11-17 | 2023-07-04 | 国网陕西省电力公司经济技术研究院 | 基于k-近邻互信息特征简化的配电网边缘侧负荷预测方法 |
| CN116179703B (zh) * | 2023-02-16 | 2024-11-15 | 厦门艾德生物医药科技股份有限公司 | 用于黑色素瘤预后的分子标记物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101142172A (zh) | 2005-01-05 | 2008-03-12 | 艾博特公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
| WO2006074430A2 (en) * | 2005-01-07 | 2006-07-13 | The Johins Hopkins University | Biomarkers for melanoma |
| WO2008031041A2 (en) * | 2006-09-07 | 2008-03-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
| ES2629749T3 (es) * | 2006-10-04 | 2017-08-14 | Dana-Farber Cancer Institute, Inc. | Inmunidad tumoral |
-
2007
- 2007-05-24 NZ NZ555363A patent/NZ555363A/en unknown
-
2008
- 2008-05-23 DK DK08766967.7T patent/DK2158332T3/da active
- 2008-05-23 TW TW103127682A patent/TWI609967B/zh not_active IP Right Cessation
- 2008-05-23 JP JP2010509293A patent/JP5943315B2/ja not_active Expired - Fee Related
- 2008-05-23 TW TW097119301A patent/TWI582236B/zh not_active IP Right Cessation
- 2008-05-23 SG SG10201912289SA patent/SG10201912289SA/en unknown
- 2008-05-23 AU AU2008253836A patent/AU2008253836B2/en not_active Ceased
- 2008-05-23 WO PCT/NZ2008/000118 patent/WO2008143533A1/en not_active Ceased
- 2008-05-23 PT PT87669677T patent/PT2158332T/pt unknown
- 2008-05-23 CA CA2725602A patent/CA2725602A1/en not_active Abandoned
- 2008-05-23 SG SG10201509568QA patent/SG10201509568QA/en unknown
- 2008-05-23 PT PT162033013T patent/PT3176270T/pt unknown
- 2008-05-23 ES ES16203301T patent/ES2821300T3/es active Active
- 2008-05-23 ES ES08766967.7T patent/ES2622858T3/es active Active
- 2008-05-23 CL CL2008001517A patent/CL2008001517A1/es unknown
- 2008-05-23 EP EP16203301.3A patent/EP3176270B1/en not_active Not-in-force
- 2008-05-23 EP EP08766967.7A patent/EP2158332B1/en not_active Not-in-force
- 2008-05-23 CN CN2008800248635A patent/CN101743327B/zh not_active Expired - Fee Related
- 2008-05-23 DK DK16203301.3T patent/DK3176270T3/da active
- 2008-05-26 AR ARP080102210A patent/AR066725A1/es active IP Right Grant
- 2008-05-26 UY UY31105A patent/UY31105A1/es active IP Right Grant
-
2009
- 2009-11-23 US US12/592,385 patent/US8822149B2/en active Active
-
2014
- 2014-08-29 US US14/472,755 patent/US9534258B2/en not_active Expired - Fee Related
- 2014-10-31 JP JP2014223331A patent/JP2015061528A/ja active Pending
-
2016
- 2016-12-14 JP JP2016242254A patent/JP6404304B2/ja not_active Expired - Fee Related
- 2016-12-27 US US15/391,293 patent/US10266902B2/en not_active Expired - Fee Related
-
2018
- 2018-09-12 JP JP2018170779A patent/JP2019004907A/ja active Pending
-
2020
- 2020-06-04 JP JP2020097666A patent/JP2020150949A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2158332T3 (da) | Prognoseforudsigelse til melanomcancer | |
| JP6824923B2 (ja) | 胃腸癌での増殖の徴候及び予後 | |
| KR101530689B1 (ko) | 직장결장암용 예후 예측 | |
| NZ555353A (en) | TNF antagonists | |
| HK1145342B (en) | Prognosis prediction for melanoma cancer |